Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer

NCT07281157 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

DRUG: Irinotecan Liposome, Capecitabine, and Enlansubemab Plus Short-Course Radiotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital